Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
24 hedge funds and large institutions have $1.74M invested in Evofem Biosciences, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 12 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
17% less funds holding
Funds holding: 29 → 24 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
92% less capital invested
Capital invested by funds: $22.1M → $1.74M (-$20.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$512K |
| 2 |
Two Sigma Investments
New York
|
+$451K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$216K |
| 4 |
Two Sigma Advisers
New York
|
+$191K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$8.65M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.01M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$987K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$917K |
| 5 |
UBS AM
Chicago,
Illinois
|
-$889K |
EVFM Hedge Fund Activity: Q4 2015 in Review
24 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2015, worth a combined $1.74M — down 92% from $22.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of EVFM and 7 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $512K. The largest seller was Clarus Ventures, exiting entirely with an estimated $8.65M sold.
- 24 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2015, down from 29 in Q3 2015.
- Funds reported $1.74M of Evofem Biosciences, Inc. Common Stock stock for Q4 2015, down 92% quarter-over-quarter.
- 7 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2015 and 12 closed out, a net change of -5 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2015 was Vanguard Group, an estimated $512K added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2015 was Clarus Ventures, an estimated $8.65M sold.
Based on aggregated 13F filings for Q4 2015.